ELAN · NYSE · Healthcare
Elanco Animal Health Incorporated (ELAN) — Rank #349 by gross profitability (GP/assets 0.19) · ROE -3.5% · Piotroski F-Score 6 / 9.
As-of 2026-10-30 · CIK 0001739104 · all metrics point-in-time as of the filing date.
About
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
Show moreShow less
The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians.
Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- elanco.com
Company Snapshot
P/S is the primary valuation lens for pre-profit companies.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
9,400
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NYSE
10/11
Flags passed
ELAN passes 10/11 quality flags
1 caution to review
- CAUTIONDisclosure regression
A previously-disclosed line item is no longer reported — worth checking the filing for why
- PASSGross margin holding
- PASSDilution within 2%
- PASSFCF not negative from investment
- PASSRevenue not declining
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSBalance sheet stable
- PASSNo competitive retreat
- PASSSBC not compressing margin
- PASSNo valuation convergence
Strengths Revenue growth accelerating · Deferred revenue growing · Sequential beat (rev + EPS)
No data Operating margin — not counted as a pass.
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passBurn rate (cash flow) is the primary read at this stage — TAM and product-market fit aren't metrics this dashboard tracks.
Profitability
Does it make money well?
No warning flags · GP/assets 0.19
Gross profitability (GP / assets)
0.19
Primary signal (Novy-Marx).
12th of 12 SIC 2834 peers
Return on equity
-3.5%
Gross margin
55.0%
12th of 12 SIC 2834 peers
Revenue growth (YoY)
6.2%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
2.2%
Revenue CAGR (5Y)
7.6%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
-3.4%
Cash Flow Health
Is the cash real?
No warning flags · FCF 222% above net income
Free cash flow
$284.00M
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
222.4%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.4%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
No warning flags · net debt $3.87B, F-Score 6/9
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.06
9th of 12 SIC 2834 peers (best = lowest)
Current ratio
2.05×
10th of 12 SIC 2834 peers
Quick ratio
0.87×
Net cash
-$3.87B
Cash & equivalents minus total debt.
Piotroski F-Score
6 / 9
Fundamental-strength score (0-9).
Valuation
Is the price reasonable?
No warning flags
Capital allocation quality
Composite score
3.0 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports